Patient SatisfactionLOVENCT04680897
LOVE Trial: Limits On Vaginal Intercourse After Mid-urEthral Sling
A study testing Early restriction release and Standard restriction recommendation in people with Patient Satisfaction and Female Sexual Dysfunction, run by Wake Forest University Health Sciences at 3 sites in United States.
Trial summary
There are no prospective, randomized studies addressing vaginal penetration restrictions following mid-urethral slings. There is a single cohort study examining expedited recovery following vaginal prolapse repair which advised 3-weeks of vaginal penetration restrictions. Read more about this study
- Who is it for?
- Ages 21 years and older, women only
- Conditions the study is for
- Patient Satisfaction, Female Sexual Dysfunction
- What is being tested?
- Early restriction release and Standard restriction recommendation
- Type of treatment
- Lifestyle or therapy programme
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 155 participants
- Where
- 3 sitesUnited States
- Study dates
- 16 Apr 2021to 27 Sep 2024
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 21 years and older
- Women only
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- At least 21years of age
- Women with stress or mixed urinary incontinence who are undergoing a planned, isolated, synthetic mid-urethral sling with cystoscopy via retropubic, transobturator or single-incision approach.
- Sexually active with ≥1 male or female partner with a frequency of at least once every 2 weeks
- Ability to comprehend the concept of randomization
- Willing to remain compliant with the instructions and study follow-up visits
Who cannot join
- History of prior surgery for incontinence including mid-urethral sling, fascial sling
- History of prior surgery for prolapse with transvaginal mesh
- Diabetic with Hgb A1C ≥ 8.0 % (elevated A1C is associated with delayed wound healing12 and 8.0 has been identified as a cutoff over which there are more complications postoperatively13
- Pregnant
- Incarcerated
- History of pelvic radiation
- Current smoker (known risk factor for mesh exposure)
- Non-English speaker
Trial locations and contacts
3 sites in 1 country.
United States3 sites
Atrium Health
Charlotte, North Carolina, 28207
Northwestern Medicine
Chicago, Illinois, 60611
Wake Forest Health Sciences
Winston-Salem, North Carolina, 27157
About this study
Official title: Limits On Vaginal Intercourse After Mid-urEthral Sling (LOVE Trial)
There are no prospective, randomized studies addressing vaginal penetration restrictions following mid-urethral slings. There is a single cohort study examining expedited recovery following vaginal prolapse repair which advised 3-weeks of vaginal penetration restrictions. This study reported an earlier return to intercourse in the 3-week group than in the retrospectively collected control group where 6-weeks of restriction were advised. This study did not evaluate the impact of early versus later return to sexual activity on wound complications, mesh exposure rates, pain or satisfaction.
It is important to develop evidenced-based recommendations on post-operative sexual activity restrictions.
The purpose of this research study is to understand if the "standard" 6-week restriction on vaginal penetration/intercourse after mid-urethral sling affects patient satisfaction
Read the detailed description
The lifetime risk of surgery for stress urinary incontinence in women is 13.6%. Women are typically instructed to avoid strenuous physical activity and vaginal penetration for 6 weeks following synthetic mid-urethral sling procedures. The historical rationale behind these instructions was to prevent disruption of vaginal incisions, promote wound healing, decrease recurrence risk and prevent complications such as mesh exposure. Very little medical evidence exists, however, to support these activity restrictions which can have a negative impact on satisfaction and quality of life. Findings from a single randomized trial challenge standard activity restrictions following pelvic organ prolapse repair. Participants were given conservative or liberal postoperative instructions and the liberal group experienced fewer prolapse and urinary symptoms at 3 months postoperatively; but there was no difference in satisfaction between groups. This study, however, did not investigate restrictions on vaginal penetration (both groups adhered to 6-week restrictions) and was not specific to women undergoing isolated sling procedures. There are no prospective, randomized studies addressing vaginal penetration restrictions following mid-urethral slings. There is a single cohort study examining expedited recovery following vaginal prolapse repair which advised 3-weeks of vaginal penetration restrictions. This study reported an earlier return to intercourse in the 3-week group than in the retrospectively collected control group where 6-weeks of restriction were advised. This study did not evaluate the impact of early versus later return to sexual activity on wound complications, mesh exposure rates, pain or satisfaction.
Animal models suggest that wound healing occurs much sooner than 6 weeks post-surgery. In fact, epithelial wounds closed by primary intention typically re-epithelialize in just 24-48 hours. In a mouse-model with full-thickness vaginal injury, there was complete restoration of mucosal integrity by day 7 without surgical closure of the wound. Epithelial healing over mid-urethral sling could differ due to a known pro-inflammatory milieu in the setting of a mesh implant but the rate of epithelial closure over implanted synthetic mesh has not been specifically described. While earlier vaginal penetration could theoretically increase the risk of mesh exposure from the known baseline risk of 2-3%, this is unlikely following two weeks in a low risk population regardless of menopausal status. Vaginal atrophy has been identified as a risk factor for wound healing complications and vaginal mesh exposure and could interact with early resumption of intercourse. However, vaginal atrophy can be reversed with vaginal estrogen therapy and resultant risks mitigated.
Given the prevalence of mid-urethral slings for stress incontinence, it is important to develop evidenced-based recommendations on post-operative sexual activity restrictions. The purpose of this randomized trial, therefore, is to evaluate the impact of early (2 weeks) versus standard (6 weeks) removal of vaginal penetration restrictions in sexually active women undergoing mid-urethral sling procedures on sexual satisfaction and wound complications.
- Conditions
- Patient Satisfaction, Female Sexual Dysfunction
- Being tested
- Early restriction release, Standard restriction recommendation
- Keywords
- mid-urethral sling
- Medical subject headings
- Patient Satisfaction
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Early restriction releaseBehavioural
Participants will no longer have restrictions on vaginal penetration 2 weeks after surgery.
Standard restriction recommendationBehavioural
Participants will return to intercourse after 6 weeks
| Study group | Role | What they receive |
|---|---|---|
| Standard Group | Other | Participants may resume vaginal penetration at 6 weeks. Receives: Behavioral: Standard restriction recommendation |
| Early Group | Other | Participants may resume intercourse at 2 weeks Receives: Behavioral: Early restriction release |
What is being measured
The primary outcome is the main question the study is designed to answer.
Participant satisfaction rating
To determine if there is improved satisfaction with decreased length of restricted vaginal penetration following mid-urethral sling. The primary outcome will be patient satisfaction with ability to return to sexual function as measured on a 5-point Likert scale with the question: "How satisfied were you with your ability to return to vaginal penetration following surgery?"
(1) Strongly disagree; (2) Disagree; (3) Neither agree nor disagree; (4) Agree; (5) Strongly agree
Measured: week 12
Secondary outcomes (7)
Number of days until resumption of vaginal penetration
Measured: week 12
Number of Wound complications - wound separation
To determine if there are increased wound complications in patients following isolated mid-urethral sling with shorter duration of restrictions on vaginal penetration.
Measured: week 12
Number of Wound complications - mesh exposure
To determine if there are increased wound complications in patients following isolated mid-urethral sling with shorter duration of restrictions on vaginal penetration.
Measured: week 12
Number of Wound complications - mesh erosion
To determine if there are increased wound complications in patients following isolated mid-urethral sling with shorter duration of restrictions on vaginal penetration.
Measured: week 12
Number of Wound complications - granulation tissue
To determine if there are increased wound complications in patients following isolated mid-urethral sling with shorter duration of restrictions on vaginal penetration.
Measured: week 12
Number of Wound complications - vaginal pain
To determine if there are increased wound complications in patients following isolated mid-urethral sling with shorter duration of restrictions on vaginal penetration.
Measured: week 12
Urinary incontinence
To determine if there is similar continence in patients who resume intercourse early vs standard following isolated mid-urethral sling
Measured: week 12
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted23 Dec 2020
- Study start16 Apr 2021
- Primary completion27 Sep 2024
- Study completion27 Sep 2024
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Patient SatisfactionStudies of the same condition, open and under way.
- More trials run by Wake Forest University Health SciencesThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Supportive care
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Model description
- The "early" group will be given instructions that allow them to return to vaginal penetration/intercourse after 2 weeks. The "standard" group will be given postoperative instructions that allow them to return to intercourse after 6 weeks. Both groups will be able to return to other physical activities as they feel able
- Masking
- Double blind
- Who is masked
- Care provider, Outcomes assessor
- Enrolment
- 155 participants (actual)
Sponsor and investigators
- Lead sponsor
- Wake Forest University Health Sciences
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- Catherine A Matthews, MD, Principal investigator, Wake Forest Health Sciences
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT04680897
- Sponsor's protocol ID
- IRB00070386
- Acronym
- LOVE
- Status last verified
- Aug 2024
- First submitted
- 17 Dec 2020
- Last updated
- 19 Mar 2025
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 19 Mar 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Limits On Vaginal Intercourse After Mid-urEthral Sling (LOVE Trial)
- ClinicalTrials.gov ID
- NCT04680897
- Acronym / sponsor ID
- LOVE / IRB00070386
- Conditions
- Patient Satisfaction, Female Sexual Dysfunction
- Keywords
- mid-urethral sling
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 155 participants (actual)
- Lead sponsor
- Wake Forest University Health SciencesUniversity, hospital or other
- Study start
- 16 Apr 2021 (actual)
- Primary completion
- 27 Sep 2024 (actual)
- Study completion
- 27 Sep 2024 (actual)
- First posted
- 23 Dec 2020 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
There are no prospective, randomized studies addressing vaginal penetration restrictions following mid-urethral slings. There is a single cohort study examining expedited recovery following vaginal prolapse repair which advised 3-weeks of vaginal penetration restrictions. This study reported an earlier return to intercourse in the 3-week group than in the retrospectively collected control group where 6-weeks of restriction were advised. This study did not evaluate the impact of early versus later return to sexual activity on wound complications, mesh exposure rates, pain or satisfaction.
It is important to develop evidenced-based recommendations on post-operative sexual activity restrictions.
The purpose of this research study is to understand if the "standard" 6-week restriction on vaginal penetration/intercourse after mid-urethral sling affects patient satisfaction
Detailed description
The lifetime risk of surgery for stress urinary incontinence in women is 13.6%. Women are typically instructed to avoid strenuous physical activity and vaginal penetration for 6 weeks following synthetic mid-urethral sling procedures. The historical rationale behind these instructions was to prevent disruption of vaginal incisions, promote wound healing, decrease recurrence risk and prevent complications such as mesh exposure. Very little medical evidence exists, however, to support these activity restrictions which can have a negative impact on satisfaction and quality of life. Findings from a single randomized trial challenge standard activity restrictions following pelvic organ prolapse repair. Participants were given conservative or liberal postoperative instructions and the liberal group experienced fewer prolapse and urinary symptoms at 3 months postoperatively; but there was no difference in satisfaction between groups. This study, however, did not investigate restrictions on vaginal penetration (both groups adhered to 6-week restrictions) and was not specific to women undergoing isolated sling procedures. There are no prospective, randomized studies addressing vaginal penetration restrictions following mid-urethral slings. There is a single cohort study examining expedited recovery following vaginal prolapse repair which advised 3-weeks of vaginal penetration restrictions. This study reported an earlier return to intercourse in the 3-week group than in the retrospectively collected control group where 6-weeks of restriction were advised. This study did not evaluate the impact of early versus later return to sexual activity on wound complications, mesh exposure rates, pain or satisfaction.
Animal models suggest that wound healing occurs much sooner than 6 weeks post-surgery. In fact, epithelial wounds closed by primary intention typically re-epithelialize in just 24-48 hours. In a mouse-model with full-thickness vaginal injury, there was complete restoration of mucosal integrity by day 7 without surgical closure of the wound. Epithelial healing over mid-urethral sling could differ due to a known pro-inflammatory milieu in the setting of a mesh implant but the rate of epithelial closure over implanted synthetic mesh has not been specifically described. While earlier vaginal penetration could theoretically increase the risk of mesh exposure from the known baseline risk of 2-3%, this is unlikely following two weeks in a low risk population regardless of menopausal status. Vaginal atrophy has been identified as a risk factor for wound healing complications and vaginal mesh exposure and could interact with early resumption of intercourse. However, vaginal atrophy can be reversed with vaginal estrogen therapy and resultant risks mitigated.
Given the prevalence of mid-urethral slings for stress incontinence, it is important to develop evidenced-based recommendations on post-operative sexual activity restrictions. The purpose of this randomized trial, therefore, is to evaluate the impact of early (2 weeks) versus standard (6 weeks) removal of vaginal penetration restrictions in sexually active women undergoing mid-urethral sling procedures on sexual satisfaction and wound complications.
Study design
- Primary purpose
- Supportive care
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind (care provider, outcomes assessor)
- Number of arms
- 2
- Model description
- The "early" group will be given instructions that allow them to return to vaginal penetration/intercourse after 2 weeks. The "standard" group will be given postoperative instructions that allow them to return to intercourse after 6 weeks. Both groups will be able to return to other physical activities as they feel able
| Arm | Type | Receives |
|---|---|---|
| Standard Group | Other | Behavioral: Standard restriction recommendationParticipants may resume vaginal penetration at 6 weeks. |
| Early Group | Other | Behavioral: Early restriction releaseParticipants may resume intercourse at 2 weeks |
Who may qualify
- Ages
- 21 years and older
- Sex
- Female only
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (5 listed)
- At least 21years of age
- Women with stress or mixed urinary incontinence who are undergoing a planned, isolated, synthetic mid-urethral sling with cystoscopy via retropubic, transobturator or single-incision approach.
- Sexually active with ≥1 male or female partner with a frequency of at least once every 2 weeks
- Ability to comprehend the concept of randomization
- Willing to remain compliant with the instructions and study follow-up visits
Key exclusion criteria (8 listed)
- History of prior surgery for incontinence including mid-urethral sling, fascial sling
- History of prior surgery for prolapse with transvaginal mesh
- Diabetic with Hgb A1C ≥ 8.0 % (elevated A1C is associated with delayed wound healing12 and 8.0 has been identified as a cutoff over which there are more complications postoperatively13
- Pregnant
- Incarcerated
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Early restriction releaseParticipants will no longer have restrictions on vaginal penetration 2 weeks after surgery. | Behavioural | Early Group |
| Standard restriction recommendationParticipants will return to intercourse after 6 weeks | Behavioural | Standard Group |
Primary outcome
Participant satisfaction rating
Time frame: week 12
To determine if there is improved satisfaction with decreased length of restricted vaginal penetration following mid-urethral sling. The primary outcome will be patient satisfaction with ability to return to sexual function as measured on a 5-point Likert scale with the question: "How satisfied were you with your ability to return to vaginal penetration following surgery?" (1) Strongly disagree; (2) Disagree; (3) Neither agree nor disagree; (4) Agree; (5) Strongly agree
7 secondary outcomes
Number of days until resumption of vaginal penetration
Time frame: week 12
Number of Wound complications - wound separation
Time frame: week 12
Number of Wound complications - mesh exposure
Time frame: week 12
Number of Wound complications - mesh erosion
Time frame: week 12
Number of Wound complications - granulation tissue
Time frame: week 12
Number of Wound complications - vaginal pain
Time frame: week 12
Urinary incontinence
Time frame: week 12
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 19 Mar 2025.
- Individual participant dataSharing planned: No
Related trials for Patient Satisfaction
Recruiting
ChatGPT & Surgeon Synergy: Redefining Breast Reconstruction Consultations for Enhanced Patient Engagement and Satisfaction
Breast Cancer, Cancer of the Breast
RecruitingObservational study
Brain Function and Psychological Changes Related to Cell Therapy for Autoimmune Hemolytic Anemia
CAR T-cell Therapy, Autoimmune Hemolytic Anemia
Active, not recruiting
The Acupuncture Treatment Effect in Patients With Schizophrenia
Mental Health
Not yet recruiting
Patient Satisfaction After Robotic-Assisted Versus Conventional Total Knee Arthroplasty
Osteoarthritis (Knee), Robotic Assisted Arthroplasty
Recruiting
Ending the HIV Epidemic: An All-facility Intervention for Patient and Healthcare Staff Well-being
Stigma, HIV
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Catherine A Matthews, MD principal investigator
Wake Forest Health Sciences
3 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Early restriction release and Standard restriction recommendation in people with Patient Satisfaction and Female Sexual Dysfunction, run by Wake Forest University Health Sciences at 3 sites in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 5 inclusion and 8 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 19 Mar 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 3 sites in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Participant satisfaction rating (time frame: week 12). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 19 Mar 2025.